Lisa Medina, NP
Nurse Practitioner · Wheat Ridge, CONPI 1629646179
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,647 and has fallen 99.0% since, to $38 in 2025. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 363 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$756
- Biogen$735
- EMD Serono, Inc.$435
- Pfizer$383
- Bristol Myers Squibb$318
- Biohaven Pharmaceutical Holding Company Ltd.$284
- plus $3K from 33 others
What the payments were for
- Food & beverage$5,48499%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 63 | $756 |
| Biogen | 48 | $735 |
| EMD Serono, Inc. | 25 | $435 |
| Pfizer | 32 | $383 |
| Bristol Myers Squibb | 22 | $318 |
| Biohaven Pharmaceutical Holding Company Ltd. | 27 | $284 |
| Amgen | 17 | $261 |
| Lilly USA, LLC | 13 | $237 |
| Sanofi | 11 | $200 |
| Tanabe Pharma America, Inc. | 9 | $165 |
| Amneal Pharmaceuticals LLC | 11 | $161 |
| Novartis | 9 | $157 |
| AstraZeneca(2 entities) | 8 | $138 |
| Argenx US, Inc. | 7 | $130 |
| Genentech USA, Inc. | 6 | $119 |
| Neurocrine Biosciences, Inc. | 6 | $118 |
| SK Life Science, Inc. | 5 | $106 |
| Mallinckrodt Hospital Products Inc. | 6 | $103 |
| Lundbeck LLC | 4 | $92 |
| Neurelis, Inc. | 5 | $83 |
| Alnylam Pharmaceuticals Inc. | 4 | $72 |
| Jazz Pharmaceuticals Inc. | 3 | $66 |
| Avanir Pharmaceuticals, Inc. | 2 | $50 |
| Harmony Biosciences LLC | 2 | $42 |
| Atricure, Inc. | 1 | $38 |
| Boston Scientific | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Eisai Inc. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 2 | $23 |
| Biohaven Pharmaceuticals, Inc. | 2 | $23 |
| Acorda Therapeutics, Inc | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Medtronic | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| MDD US Operations, LLC | 1 | $17 |
| Sobi, Inc | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$5,546 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 42 | $81,926 |
| BriviactBrivaracetam | 28 | $41,224 |
| QuliptaAtogepant | 21 | $40,401 |
| UbrelvyUbrogepant | 19 | $25,496 |
| Emgality PenGalcanezumab-Gnlm | 34 | $23,875 |
| Carbamazepine ErCarbamazepine | 23 | $2,447 |
| Lacosamide | 22 | $1,492 |
| Levetiracetam | 28 | $901 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $428 |
| Donepezil Hcl | 32 | $203 |
| Sumatriptan Succinate | 12 | $114 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 12 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $383 | $81,92642 claims |
| AbbVieQulipta, Ubrelvy | $756 | $65,89740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Other nurse practitioner in Wheat Ridge
- Sara SchmidtWheat Ridge$8K
- Deborah HinnenColorado Springs$388K
- Christina HansonLone Tree$381K
- Kara HartPueblo$142K
- Amy SidorskiAurora$97K
- Lori WenzGrand Junction$54K
- Lisa KeithColorado Springs$52K
- Victoria SegroEnglewood$29K
- Christina ProulxDenver$28K
- Jose Diaz LeoDenver$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.